Alirocumab

Evidence Level: L5

Predicted Indications: 10

Alirocumab

Pharmacist Assessment Report

Alirocumab: From Dyslipidemia and Atherosclerosis to Ichthyosis, X-linked, without Steroid Sulfatase Deficiency

One-Sentence Summary

Alirocumab is a PCSK9-inhibiting monoclonal antibody, originally used to lower cholesterol in dyslipidemia and atherosclerotic disease. The TxGNN model predicts it may be effective for X-linked ichthyosis (without steroid sulfatase deficiency), but no clinical trials and no publications currently support this prediction, so it is a model-only signal.

Quick Overview

Item	Content
Original Indication	Dyslipidemia and atherosclerotic disease (syndromic dyslipidemia, arteriosclerosis disorder, atherosclerosis, arteriolosclerosis); the Canadian licence records contain no indication text
Predicted New Indication	Ichthyosis, X-linked, without steroid sulfatase deficiency
TxGNN Prediction Score	0.9943
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, alirocumab is a fully human antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). Blocking PCSK9 increases the number of LDL receptors available on liver cells and lowers circulating LDL cholesterol. Its efficacy in lipid lowering is established.

The link to the predicted indication is weak. X-linked ichthyosis is a skin disorder associated with cholesterol sulfate accumulation. No supported pathway connecting PCSK9 inhibition to this condition is evident from the available data. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence; it should not be read as evidence of benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02453835	PRALUENT	Not listed	Not listed
02547732	PRALUENT	Not listed	Not listed
02453819	PRALUENT	Not listed	Not listed

Safety Considerations

Drug Interactions: The interaction query completed and returned one entry, which is a pharmacological target relationship rather than a drug-drug interaction. Alirocumab binds its target, PCSK9 (human). No interacting drugs with a defined severity level were identified.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone. There are no trials or publications for this disease, and the mechanistic link between PCSK9 inhibition and X-linked ichthyosis is speculative.

To proceed, the following is needed:

Any preclinical or clinical evidence linking PCSK9 inhibition to the pathophysiology of X-linked ichthyosis
Mechanism of action data and Health Canada package insert warnings and contraindications, to support safety screening
Route compatibility assessment, since this is a skin disease and alirocumab is a systemic injectable
Comparison with other predicted indications. For example, xanthomatosis has indirect, case-level literature and a plausible LDL-lowering rationale, and “cholesterol catabolic process disease” has review-level literature, though that largely overlaps with alirocumab’s existing lipid-lowering use.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.